These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37255194)

  • 1. Pharmacokinetics of YK-1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Li Y; Yan B; Guo S; Tian M; Li Y; Tong H; Yu Y; Shao J; Xin Y; Chen H; Xu B; Li X
    Br J Clin Pharmacol; 2023 Oct; 89(10):3067-3078. PubMed ID: 37255194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Ceftazidime/Avibactam Administration in
    Dai Y; Chang W; Zhou X; Yu W; Huang C; Chen Y; Ma X; Lu H; Ji R; Ying C; Wang P; Liu Z; Yuan Q; Xiao Y
    Drug Des Devel Ther; 2021; 15():2899-2905. PubMed ID: 34262257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.
    Das S; Fitzgerald R; Ullah A; Bula M; Collins AM; Mitsi E; Reine J; Hill H; Rylance J; Ferreira DM; Tripp K; Bertasini A; Franzoni S; Massimiliano M; Lahlou O; Motta P; Barth P; Velicitat P; Knechtle P; Hope W
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers.
    Wu XJ; Zhang J; Guo BN; Zhang YY; Yu JC; Cao GY; Chen YC; Zhu DM; Ye XY; Wu JF; Shi YG; Chang LW; Chang YT; Tsai CY
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1446-54. PubMed ID: 25534726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal AnaerobicInfection.
    Wu H; Xie S; Yu J; Chen Y; Wu J; Guo B; Zhu Z; Zhou Y; Wang Z; Zhang J
    Clin Ther; 2018 Sep; 40(9):1548-1555. PubMed ID: 30146271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
    Bilal M; Zoller M; Fuhr U; Jaehde U; Ullah S; Liebchen U; Büsker S; Zander J; Babouee Flury B; Taubert M
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0030923. PubMed ID: 37366614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers.
    Edwina AE; Koch BCP; Muller AE; Al Jalali V; Matzneller P; Zeitlinger M; Sassen SDT
    Eur J Clin Pharmacol; 2023 Jun; 79(6):775-787. PubMed ID: 37060459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of i.v. push administration on β-lactam pharmacodynamics.
    Butterfield-Cowper JM; Burgner K
    Am J Health Syst Pharm; 2017 May; 74(9):e170-e175. PubMed ID: 28438821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
    Albiero J; Sy SK; Mazucheli J; Caparroz-Assef SM; Costa BB; Alves JL; Gales AC; Tognim MC
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4128-39. PubMed ID: 27139468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.